Arch Venture Fund Vii, L.p. - Net Worth and Insider Trading
Arch Venture Fund Vii, L.p. Net Worth
The estimated net worth of Arch Venture Fund Vii, L.p. is at least $164 Million dollars as of 2024-09-20. Arch Venture Fund Vii, L.p. is the 10% Owner of Juno Therapeutics Inc and owns about 1,097,015 shares of Juno Therapeutics Inc (JUNO) stock worth over $95 Million. Arch Venture Fund Vii, L.p. is the 10% Owner of Twist Bioscience Corp and owns about 954,146 shares of Twist Bioscience Corp (TWST) stock worth over $46 Million. Arch Venture Fund Vii, L.p. is also the 10% Owner of 908 Devices Inc and owns about 5,725,045 shares of 908 Devices Inc (MASS) stock worth over $22 Million. Besides these, Arch Venture Fund Vii, L.p. also holds Syros Pharmaceuticals Inc (SYRS) . Details can be seen in Arch Venture Fund Vii, L.p.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Arch Venture Fund Vii, L.p. has not made any transactions after 2020-12-22 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Arch Venture Fund Vii, L.p.
Arch Venture Fund Vii, L.p. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Arch Venture Fund Vii, L.p. owns 11 companies in total, including Syros Pharmaceuticals Inc (SYRS) , Twist Bioscience Corp (TWST) , and Unity Biotechnology Inc (UBX) among others .
Click here to see the complete history of Arch Venture Fund Vii, L.p.’s form 4 insider trades.
Insider Ownership Summary of Arch Venture Fund Vii, L.p.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| SYRS | Syros Pharmaceuticals Inc | 2019-07-17 | 10 percent owner |
| TWST | Twist Bioscience Corp | 2018-11-02 | 10 percent owner |
| UBX | Unity Biotechnology Inc | 2018-05-02 | 10 percent owner |
 | | 2018-04-03 | other: Former 10% owner |
| | 2016-05-23 | 10 percent owner |
| | 2016-03-15 | 10 percent owner |
| | 2015-01-14 | 10 percent owner |
| | 2014-06-23 | 10 percent owner |
| | 2013-06-18 | 10 percent owner |
| | 2020-12-22 | 10 percent owner |
| | 2023-09-14 | 10 percent owner |
Arch Venture Fund Vii, L.p. Latest Holdings Summary
Arch Venture Fund Vii, L.p. currently owns a total of 4 stocks. Among these stocks, Arch Venture Fund Vii, L.p. owns 1,097,015 shares of Juno Therapeutics Inc (JUNO) as of December 18, 2014, with a value of $95 Million and a weighting of 58.16%. Arch Venture Fund Vii, L.p. owns 954,146 shares of Twist Bioscience Corp (TWST) as of November 2, 2018, with a value of $46 Million and a weighting of 27.92%. Arch Venture Fund Vii, L.p. also owns 5,725,045 shares of 908 Devices Inc (MASS) as of December 22, 2020, with a value of $22 Million and a weighting of 13.4%. The other 1 stocks Syros Pharmaceuticals Inc (SYRS) have a combined weighting of 0.52% among all his current holdings.
Latest Holdings of Arch Venture Fund Vii, L.p.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| JUNO | Juno Therapeutics Inc | 2014-12-18 | 1,097,015 | 86.96 | 95,396,424 |
| TWST | Twist Bioscience Corp | 2018-11-02 | 954,146 | 47.99 | 45,789,467 |
| MASS | 908 Devices Inc | 2020-12-22 | 5,725,045 | 3.84 | 21,984,173 |
| SYRS | Syros Pharmaceuticals Inc | 2019-07-17 | 424,205 | 2.00 | 848,410 |
Holding Weightings of Arch Venture Fund Vii, L.p.
Arch Venture Fund Vii, L.p. Form 4 Trading Tracker
According to the SEC Form 4 filings, Arch Venture Fund Vii, L.p. has made a total of 0 transactions in Juno Therapeutics Inc (JUNO) over the past 5 years. The most-recent trade in Juno Therapeutics Inc is the sale of 0 shares on December 18, 2014, which brought Arch Venture Fund Vii, L.p. around $0.
According to the SEC Form 4 filings, Arch Venture Fund Vii, L.p. has made a total of 0 transactions in Twist Bioscience Corp (TWST) over the past 5 years. The most-recent trade in Twist Bioscience Corp is the acquisition of 75,000 shares on November 2, 2018, which cost Arch Venture Fund Vii, L.p. around $1 Million.
According to the SEC Form 4 filings, Arch Venture Fund Vii, L.p. has made a total of 1 transactions in 908 Devices Inc (MASS) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in 908 Devices Inc is the acquisition of 300,000 shares on December 22, 2020, which cost Arch Venture Fund Vii, L.p. around $6 Million.
More details on Arch Venture Fund Vii, L.p.'s insider transactions can be found in the Insider Trading History of Arch Venture Fund Vii, L.p. table.Insider Trading History of Arch Venture Fund Vii, L.p.
- 1
Arch Venture Fund Vii, L.p. Trading Performance
GuruFocus tracks the stock performance after each of Arch Venture Fund Vii, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Arch Venture Fund Vii, L.p. is 11.64%. GuruFocus also compares Arch Venture Fund Vii, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Arch Venture Fund Vii, L.p. within 3 months outperforms 1 times out of 3 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Arch Venture Fund Vii, L.p.'s insider trading performs compared to the benchmark.
Performance of Arch Venture Fund Vii, L.p.
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 20.55 | | | | | |
| Relative Return to S&P 500(%) | 17.39 | | | | | |
Arch Venture Fund Vii, L.p. Ownership Network
Arch Venture Fund Vii, L.p. Owned Company Details
What does Syros Pharmaceuticals Inc do?
Who are the key executives at Syros Pharmaceuticals Inc?
Arch Venture Fund Vii, L.p. is the 10 percent owner of Syros Pharmaceuticals Inc. Other key executives at Syros Pharmaceuticals Inc include Chief Financial Officer Jason Haas , Chief Commercial Officer Chee Conley , and Chief Medical Officer David Roth .
Syros Pharmaceuticals Inc (SYRS) Insider Trades Summary
Over the past 18 months, Arch Venture Fund Vii, L.p. made no insider transaction in Syros Pharmaceuticals Inc (SYRS). Other recent insider transactions involving Syros Pharmaceuticals Inc (SYRS) include a net sale of 30,523 shares made by David Roth , a net purchase of 904,977 shares made by Srinivas Akkaraju , and a net purchase of 100,000 shares made by Jason Haas .
In summary, during the past 3 months, insiders sold 0 shares of Syros Pharmaceuticals Inc (SYRS) in total and bought 200,000 shares, with a net purchase of 200,000 shares. During the past 18 months, 31,212 shares of Syros Pharmaceuticals Inc (SYRS) were sold and 1,104,977 shares were bought by its insiders, resulting in a net purchase of 1,073,765 shares.
Syros Pharmaceuticals Inc (SYRS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Syros Pharmaceuticals Inc Insider Transactions
Arch Venture Fund Vii, L.p. Mailing Address
Above is the net worth, insider trading, and ownership report for Arch Venture Fund Vii, L.p.. You might contact Arch Venture Fund Vii, L.p. via mailing address: 8755 W Higgins, Suite 1025, Chicago Il 60631.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
